Merck to invest $1 billion in U.S. drug manufacturing plant

It will build a Wilmington, Delaware facility dedicated to making its cancer drug, Keytruda, for U.S. patients.

• Apr 29, 2025

Moderna announces test results for skin cancer vaccine

A vaccine and cancer drug dramatically improved survival rates for those with severe melanomas, results after three years showed.

• Dec 14, 2023

Merck sues government over Medicare drug pricing, claiming "extortion"

Drugmaker says it's unconstitutional for the feds to negotiate drug prices on behalf of seniors. Patient advocates say it's "desperately needed."

• Jun 6, 2023

Drug companies report progress on potential skin cancer vaccine

Moderna's stock soared after the COVID-19 vaccine maker detailed progress in developing a potential preventive shot for melanoma, a deadly form of skin cancer.

• Dec 13, 2022

10/11: CBSN AM

Merck seeks emergency approval for COVID-19 pill; Missing boy in Texas found alive after desperate search

• Oct 11, 2021
• 44:06

Concerns mount over COVID vaccination rates

The rate of coronavirus vaccinations in the U.S. continues to slow down. This comes as President Biden's goal to get at least 70% of Americans partially vaccinated by July 4 looms. CBS News reporter Alex Tin joins CBSN's "Red & Blue" with the latest updates on the COVID pandemic.

• Jun 9, 2021
• 09:07

New oral COVID treatment shows promising results

A new study shows an oral COVID-19 treatment from Merck reduces the risk of hospitalization and death. CBS News medical contributor, Dr. David Agus joins “CBS Mornings” to discuss.

• Oct 1, 2021
• 02:26

U.S. COVID cases surge ahead of holidays

New cases of the Omicron variant are spreading rapidly in the U.S. ahead of the holidays. People are dealing with long lines at testing sites across the nation. At-home testing kits are also short in supply and pharmacies are limiting how many customers can buy. CBS News correspondent Nancy Chen reports from New York City. Then critical care physician Dr. Lakshmana Swamy joins CBSN's Debra Alfarone to discuss the latest on the pandemic.

• Dec 23, 2021
• 08:27

FDA approves second COVID treatment pill

The FDA has authorized the second antiviral pill to treat COVID-19. CBS News' Michael George reports. Then Dr. Jeremy Faust, emergency physician at Brigham and Women's Hospital at Harvard Medical School, joins CBSN to break down how the drugs work. He also explains why he thinks the CDC should implement "circuit breakers," short-term restrictions on high-risk activities to help curb the spread of the Omicron variant.

• Dec 23, 2021
• 09:36

Omicron spike collides with holiday travel surge

The FDA authorized the first pill to treat COVID-19. The milestone comes as U.S. cases, hospitalizations and deaths are all rising, with health officials warning of a possible tsunami of new Omicron cases that could overwhelm hospitals. Nancy Chen has the details.

• Dec 22, 2021
• 04:13

FDA's advisory committee backs Merck's COVID pill

The U.S. may soon be implementing new testing requirements for travelers entering the U.S. amid growing concerns over the new COVID Omicron variant. This week a panel of FDA advisers voted to endorse Merck’s COVID-19 antiviral pill for high-risk individuals. Infectious diseases physician at Brigham and Women's Hospital and chair of that FDA panel, Dr. Lindsey Baden, joins CBSN AM to discuss.

• Dec 1, 2021
• 09:37

FDA advisers endorse Merck's COVID antiviral drug in narrow vote

The vote paves the way for the agency to authorize molnupiravir for emergency use in American adults.

• Dec 1, 2021

Pfizer says COVID pill reduces severe illness

Pfizer says its antiviral COVID-19 pill is 89% effective at prevent hospitalizations and 100% effective against deaths from the virus if taken within three days of a person experiencing symptoms. Dr. John Moore, professor of microbiology and immunology at Weill Cornell Medical College, joins CBSN's Tanya Rivero to discuss the potentially life-saving drug.

• Nov 5, 2021
• 05:59

Doctor on COVID antiviral pills and vaccines

Pfizer and Merck have both developed antiviral pills that could help reduce the risk of hospitalization or death from COVID-19. Dr. Giridar Malyah, senior policy officer at the Robert Wood Johnson Foundation, joins CBSN to discuss the latest on the coronavirus pandemic.

• Nov 5, 2021
• 08:20

COVID antiviral pill approved in the U.K.

A new antiviral drug that is taken orally to treat COVID-19 has been authorized by medical officials in the U.K. The pill from Merck is for people with mild to moderate symptoms or those considered "high risk." CBS News foreign correspondent Imtiaz Tyab joins CBSN anchors Vladimir Duthiers and Anne-Marie Green from London with details.

• Nov 4, 2021
• 13:45

U.S. COVID-19 infections continue downward trend

Coronavirus infections in the U.S. are declining from their latest peak but experts warn of a possible rough winter ahead. CBS News correspondent Manuel Bojorquez has the day's coronavirus headlines. Then Dr. Andrew Bazemore, a family medicine physician and the senior vice president of research and policy at the American Board of Family Medicine, joins CBSN"s Elaine Quijano to discuss the latest.

• Oct 11, 2021
• 07:24

Merck seeks FDA authorization for COVID pill

Drugmaker Merck is asking the FDA for an emergency use authorization for an oral pill to treat COVID-19. Manuel Bojorquez reports.

• Oct 11, 2021
• 02:00

Merck asks FDA to authorize first pill to treat COVID-19

The giant drugmaker is seeking the emergency authorization for molnupiravir, which it says cut hospitalizations and deaths by half among patients with early COVID-19 symptoms.

• Oct 11, 2021

Merck seeks FDA authorization for COVID pill

Merck has asked the FDA for emergency authorization for what would be the first pill to treat COVID-19. CBS News' Skyler Henry reports on the latest. Then Dr. Eric Cioe-Pena, director of global health at Northwell Health, joined CBSN's Tanya Rivero to discuss that plus the timeline on vaccines for kids.

• Oct 11, 2021
• 06:50

Study: COVID pill cuts deaths in half

Pharmaceutical company Merck says its experimental pill significantly reduces the effects of COVID-19 and plans to submit its findings to the Food and Drug Administration for emergency use authorization. CBS News researcher Max Bayer speaks with CBSN's Tanya Rivero about how this drug differs from those already in use.

• Oct 1, 2021
• 04:07

Doctor on COVID treatment, rural death toll

Merck says clinical trials show its antiviral pill for COVID-19 can reduce hospitalizations and deaths by half in people recently infected with the virus. Meanwhile, new data shows how hard the virus is hitting rural areas of the U.S. Dr. Ali Mokdad, chief strategy officer for Population Health at the University of Washington, joins CBSN to discuss the latest on the pandemic, plus new research in the medical journal The Lancet about deaths at the hands of police.

• Oct 1, 2021
• 07:24

Merck reports promising results from experimental COVID-19 pill

Company says molnupiravir cut hospitalizations and deaths by half in people recently infected with the virus and it will soon ask authorities to approve the pill's use.

• Oct 1, 2021

Violence against nurses increases amid pandemic

A new report by National Nurses United finds about 31% of hospital nurses say they have seen an increase in workplace violence. Justin Gill, an urgent care nurse practitioner, health policy lecturer and vice president of the Washington State Nurses Association, joins CBSN to discuss the survey, as well as efforts by Merck to develop an oral antiviral drug to fight COVID-19.

• Sep 30, 2021
• 10:17

CEO quit Trump council

After the President Trump's response to the violence in Charlottesville, Virginia, the CEOs of Under Armour, Intel, Merck and the Alliance for American Manufacturing stepped down from the Presidential Council on Manufacturing. The president of the AFL-CIO announced Tuesday night he would do so as well. Julianna Goldman reports.

• Aug 15, 2017
• 02:03

Germany's Bayer plans to buy Merck's consumer care business for $14.2 billion, plus more MoneyWatch headlines

Germany's Bayer plans to buy Merck's consumer care business for $14.2 billion. That includes products from Coppertone, Claritin and Dr. Scholl's. Merck is based in New Jersey. Jill Wagner has that story and more MoneyWatch headlines.

• May 6, 2014
• 01:09

Show More